This study found that pediatric alopecia areata patients had significantly lower serum BDNF levels compared to healthy controls, which were associated with greater alopecia severity, higher depressive symptoms, and poorer quality of life.
December 2025 in “Педиатрическая фармакология” In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.
1 citations
,
October 2025 in “Journal of Dermatological Treatment” This case study reported that Dupilumab treatment improved eczema, itch, and hair condition in a girl with Netherton Syndrome, as shown by over 40% improvement in various dermatological scores; however, significant flares of ichthyosis linearis circumflexa persisted.
7 citations
,
April 2024 in “International Journal of Dermatology” Alopecia areata greatly affects the quality of life for children and their families.
2 citations
,
September 2024 in “International Journal of Dermatology” This study by Yücesoy et al. reported that pediatric alopecia areata significantly impacts the quality of life for both affected children and their caregivers, with parents of female patients experiencing more HRQoL challenges.